Clinical Trials - PHAR

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06990529Long-term Safety and Efficacy of Leniolisib in PIDs With Immune DysregulationRECRUITINGPHASE22025-04-292029-04-132028-09-18
NCT06897358Leniolisib for Immune Dysregulation in CVIDRECRUITINGPHASE22025-02-122026-102026-10
NCT06549114Leniolisib for Immune Dysregulation in PIDsRECRUITINGPHASE22024-10-212025-102025-10
NCT05693129Pediatric Patients Aged 1 to 6 Years With APDSACTIVE_NOT_RECRUITINGPHASE32023-08-302026-02-282025-04-09
NCT06249997An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDSRECRUITINGPHASE32023-08-032025-03-312025-01-31
NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSACTIVE_NOT_RECRUITINGPHASE32023-02-012025-12-302025-07-28
NCT04912141Prevention of Acute Kidney Injury in Patients With NSTEMITERMINATEDPHASE22021-04-212023-04-282023-04-28
NCT04530136Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19COMPLETEDPHASE22020-11-302021-12-012021-09-07
NCT02859727Extension to the Study of Efficacy of CDZ173 in Patients with APDS/PASLITERMINATEDPHASE2, PHASE32016-09-082025-01-302025-01-30
NCT02247739A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCOMPLETEDPHASE22014-122016-092016-05
NCT01359969Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCOMPLETEDPHASE22012-01-172017-07-172017-07-17
NCT01188564Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCOMPLETEDPHASE32011-012013-032012-12
NCT01035593Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal TransplantationWITHDRAWNPHASE22010-122011-122011-12
NCT00851409A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCOMPLETEDPHASE22009-062010-042010-03
NCT00225147Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCOMPLETEDPHASE2, PHASE32005-072010-012009-10
NCT00262301Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCOMPLETEDPHASE32004-062009-102009-07
NCT00262288Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCOMPLETEDPHASE2, PHASE32004-042007-012007-01
NCT00261053Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCOMPLETEDPHASE22003-062005-122005-09